Definitive Surgical Treatment of 24 Skin Cancers Not Cured by Prior imiquimod Therapy: A Case Series

摘要

In 2004 imiquimod (Aldara, 3M, St. Paul, MN) was approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of superficial basal cell carcinoma (BCC), based on two double-blind, vehicle-controlled clinical studies. Imiquimod cream is indicated for the topical treatment of biopsy-confirmed, primary superficial BCC in immunocompetent adults, with a maximum tumor diameter of 2.0 cm, located on the trunk (excluding anogenital skin), neck, or extremities (excluding hands and feet), only when surgical methods are medically less appropriate and patient follow-up can be reasonably assured